SelectQuote (SLQT) Panoramica del titolo
SelectQuote, Inc. gestisce una piattaforma di distribuzione e coinvolgimento diretta al consumatore, basata sulla tecnologia, che vende polizze assicurative e servizi sanitari negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
SLQT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di SelectQuote, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$0.50 |
| Massimo di 52 settimane | US$2.22 |
| Minimo di 52 settimane | US$0.48 |
| Beta | 1.69 |
| Variazione di 1 mese | -31.39% |
| Variazione a 3 mesi | -45.53% |
| Variazione di 1 anno | -76.08% |
| Variazione a 3 anni | -59.68% |
| Variazione a 5 anni | -96.61% |
| Variazione dall'IPO | -98.15% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 09
SLQT: Softer Revenue Outlook And FY26 Guidance Will Shape Future P/E
Analysts have reduced their price target on SelectQuote from $5 to $3, citing softer revenue expectations and lower projected fiscal 2027 revenue of about $1.4b and adjusted EBITDA of roughly $98.8m compared with prior estimates. What’s in the News for SelectQuote SelectQuote issued earnings guidance for fiscal 2026, with revenue expected in a range of $1.35 billion to $1.45 billion.
Aggiornamento narrativa • Aug 26
SLQT: Improved Profitability And Reset Expectations Will Support Future Upside
Analysts have trimmed their fair value estimate for SelectQuote, with the price target moving from about $3.06 to roughly $2.31. They cite softer revenue expectations into fiscal 2027, even as profitability metrics improved and future P/E assumptions reset to more conventional levels.Recent updates
Aggiornamento narrativa • Sep 09
SLQT: Softer Revenue Outlook And FY26 Guidance Will Shape Future P/E
Analysts have reduced their price target on SelectQuote from $5 to $3, citing softer revenue expectations and lower projected fiscal 2027 revenue of about $1.4b and adjusted EBITDA of roughly $98.8m compared with prior estimates. What’s in the News for SelectQuote SelectQuote issued earnings guidance for fiscal 2026, with revenue expected in a range of $1.35 billion to $1.45 billion.Aggiornamento narrativa • Aug 26
SLQT: Improved Profitability And Reset Expectations Will Support Future Upside
Analysts have trimmed their fair value estimate for SelectQuote, with the price target moving from about $3.06 to roughly $2.31. They cite softer revenue expectations into fiscal 2027, even as profitability metrics improved and future P/E assumptions reset to more conventional levels.Aggiornamento narrativa • Jun 25
SLQT: FY26 Guidance Reaffirmation Will Support Future P/E Re Rating
Analysts have adjusted their SelectQuote price target to reflect updated assumptions for discount rate, expected revenue growth of 2.67%, profit margin of 11.06% and a forward P/E of 1.57x. This results in a revised fair value estimate of $1.25 per share, unchanged from the prior $1.25.
Aggiornamento narrativa • Jun 06
SLQT: Earnings Outlook And Margin Improvement Will Support Future Upside Potential
Analysts have revised their SelectQuote price target to $5.00 to reflect updated assumptions, including a slightly lower revenue growth outlook, a modestly higher profit margin, and a revised discount rate and forward P/E that together indicate a more measured risk and valuation profile. What's in the News SelectQuote reaffirmed earnings guidance for Fiscal Year 2026, with revenue expected in a range of US$1.61b to US$1.71b.Aggiornamento narrativa • May 21
SLQT: Local Franchise Rollout And FY26 Guidance Will Support Future P/E Re Rating
Analysts have adjusted their price target on SelectQuote to $1.25, with the change mainly tied to updated assumptions for the discount rate, revenue growth, profit margin, and future P/E rather than a shift in their overall fair value estimate. What's in the News SelectQuote reaffirmed its earnings guidance for Fiscal Year 2026, calling for revenue in a range of US$1.61b to US$1.71b (Key Developments).Aggiornamento narrativa • May 04
SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential
SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.Aggiornamento narrativa • Apr 20
SLQT: Local Franchise Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.Aggiornamento narrativa • Apr 06
SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside
Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.Aggiornamento narrativa • Mar 22
SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.Aggiornamento narrativa • Mar 07
SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside
Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.Aggiornamento narrativa • Feb 21
SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside
Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.Aggiornamento narrativa • Feb 07
SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential
Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.Articolo di analisi • Feb 06
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...Seeking Alpha • Feb 01
SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)
Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking AlphaAggiornamento narrativa • Jan 23
SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating
Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.Aggiornamento narrativa • Jan 09
SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating
Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.Aggiornamento narrativa • Dec 19
SLQT: Expanded Senior Support Services Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.Aggiornamento narrativa • Dec 05
SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.Aggiornamento narrativa • Nov 21
SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support
Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.Articolo di analisi • Nov 15
Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding
The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...Aggiornamento narrativa • Nov 07
SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks
SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).Articolo di analisi • Aug 31
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Articolo di analisi • Jul 16
SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks
When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...Seeking Alpha • Apr 28
SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)
Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
Nuova narrativa • Mar 26
Agent Efficiency And Medicare Services Will Transform 2025 Outlook
Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.Seeking Alpha • Feb 11
SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)
Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking AlphaArticolo di analisi • Jan 18
SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward
Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...Articolo di analisi • Nov 20
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company
Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...Articolo di analisi • Nov 07
SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50
It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...Articolo di analisi • Oct 03
SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...Articolo di analisi • Jul 02
SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares
When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...Articolo di analisi • Feb 13
Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Rendimenti per gli azionisti
| SLQT | US Insurance | US Mercato | |
|---|---|---|---|
| 7D | -6.8% | -2.3% | -0.9% |
| 1Y | -76.1% | 2.0% | 14.2% |
Ritorno vs Industria: SLQT ha avuto una performance inferiore rispetto al US Insurance che ha registrato un rendimento 2 % nell'ultimo anno.
Rendimento vs Mercato: SLQT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 14.2 % nell'ultimo anno.
Volatilità dei prezzi
| SLQT volatility | |
|---|---|
| SLQT Average Weekly Movement | 13.8% |
| Insurance Industry Average Movement | 4.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di SLQT è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 14% ) di SLQT è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1985 | 4,039 | Tim Danker | www.selectquote.com |
SelectQuote, Inc. gestisce una piattaforma tecnologica di distribuzione e interazione diretta con i consumatori che commercializza polizze assicurative e servizi sanitari negli Stati Uniti. La società opera attraverso tre segmenti: Senior, Servizi sanitari e Vita. Offre prodotti relativi all’assicurazione sanitaria per anziani, quali Medicare Advantage, Medicare Supplement, Medicare Parte D e altri prodotti accessori, oltre a svolgere attività di generazione di lead; polizze vita a termine, assicurazioni per le spese funerarie e altri prodotti accessori; prodotti assicurativi non commerciali per auto, casa, proprietà e responsabilità civile.
SelectQuote, Inc. Riepilogo dei fondamenti
| SLQT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$88.29m |
| Utili (TTM) | -US$11.65m |
| Ricavi(TTM) | US$1.62b |
0.1x
Rapporto P/S-7.6x
Rapporto P/ESLQT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SLQT Conto economico (TTM) | |
|---|---|
| Ricavi | US$1.62b |
| Costo del fatturato | US$1.04b |
| Profitto lordo | US$575.60m |
| Altre spese | US$587.25m |
| Utili | -US$11.65m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.066 |
| Margine lordo | 35.56% |
| Margine di profitto netto | -0.72% |
| Rapporto debito/patrimonio netto | 56.9% |
Come si è comportato SLQT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/13 05:16 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
SelectQuote, Inc. è coperta da 10 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Steven Valiquette | Barclays |
| Daniel Grosslight | Citigroup Inc |
| George Sutton | Craig-Hallum Capital Group LLC |